Clinical Trial

A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB11 PFS with intravitreal injection to trial participants with nAMD, Macular Oedema Secondary to RVO, or Myopic Choroidal Neovascularization (mCNV).
Trial Details
NCT Number NCT07550504
Lead Sponsor Samsung Bioepis Co., Ltd.
Conditions Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
Enrollment 30 participants
Start Date 2026-03-30
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-24